Overview of Hepatocellular Carcinoma Provided By New Report
Research and Markets (http://www.researchandmarkets.com/reports/c63089) has announced the addition of “Stakeholder Opinions: Hepatocellular Carcinoma – Opportune Indication For Novel Therapies” to their offering.
The close association with hepatitis means that hepatocellular carcinoma (HCC) is common in developing countries where hepatitis B and C infections are endemic. However, the increasing prevalence of hepatitis in the West means that incidence of HCC in the US and Europe is expected to increase significantly over the coming years.
Scope of this title:
Overview of hepatocellular carcinoma, including epidemiology, staging, prognosis and unmet needs Review of current treatment modalities and physician opinion of existing and future treatment strategies Evaluation of key drugs currently used in the treatment of hepatocellular carcinoma Review of late-phase drugs in development for hepatocellular carcinoma including key opinion leaders view on their potential
Highlights of this title:
Typically a disease of the developing countries, incidence of HCC is increasing in the West due to increasing cases of hepatitis infection, thus representing a revenue opportunity for pharmaceutical and biotechnology companies with targeted therapies. HCC patients are poorly served by existing treatment options, with only a small proportion amenable to curative therapy such as surgical resection and liver transplantation. Prognosis is poor for unresectable patients, and there remains no standard drug therapy for advanced HCC. Given the lack of standard of care, R&D interest in HCC is relatively high, with 37 compounds in clinical development. The majority consist of targeted therapies, with Bayer-Schering/Onyxs Nexavar, Genentech/Roches Avastin and OSI/Genentech/Roches Tarceva considered to have the highest clinical and commercial potential.
Reasons to order your copy:
Evaluate opportunities and risks in the HCC market by analyzing the clinical and commercial potential of key pipeline drugs Review critical factors that drive the HCC market to assess the potential of existing and pipeline drugs for the disease Understand current and future competitive dynamics of HCC to determine the attractiveness of the market
About Us HEALTHCARE 2
About the Oncology pharmaceutical analysis team 2
Andrew Paramore – Oncology Lead Analyst & Head of Product Development 2
Contents:
Chapter 1.
-Executive summary
Chapter 2.
-Hcc overview
Chapter 3.
-Current treatment options
Chapter 4.
-Chemotherapy regimens in unresectable hcc
Chapter 5.
-Unmet needs
Chapter 6.
-Hcc pipeline analysis
List of Tables
List of Figures
For more information visit http://www.researchandmarkets.com/reports/c63089
Source: Datamonitor